November & December 2020
January & February 2021

Online event

Webinar 'Photonics against COVID-19'

Tuesday 24 November
15:00 - 17:00

Luc Scheres

Surfix

Title: From photonics to diagnostics

Abstract

Surfix is developing an ultrasensitive photonic biochip based on a combination of silicon nitride waveguide technology, microfluidics, and nanocoatings. The biochip will be integrated in a Point-of-Care (PoC) diagnostic device for detecting biomarkers for covid-19.
To exploit the full potential of photonics in biological applications, accurate control of surface properties is essential. Surfix has developed nanocoatings that improve the sensitivity and limit of detection of photonic biosensors.
Nanocoatings also play an important role when combining photonics with microfluidics. Surfix’s nanocoatings optimize wettability and minimize non-specific adsorption of biomolecules in microfluidic devices. Moreover, the nanocoating facilitates hybrid bonding of the photonic chip to a plastic microfluidic flow cell.
In this contribution, recent developments and current status of the photonic biochip will be presented.

Biography

Luc is the Chief Technology Officer of Surfix. In 2005 he received his MSc degree in Chemistry and Physics at Utrecht University. Subsequently Luc moved to Wageningen University and obtained his PhD degree (with highest honors) in 2010. After a short post-doc at Eindhoven University Luc founded Surfix in 2011.

Company description:

Building on its portfolio of proprietary nanocoating technologies, Surfix provides nanocoating-enhanced components for Point-of-Care (PoC) diagnostic devices and other Lab-on-a-Chip applications. The main goal is the development of a photonic biosensor platform to facilitate diagnosis and treatment of covid-19, cancer, and other conditions.